Top Markets
Coin of the day
Galera Therapeutics, Inc. Galera Therapeutics, Inc.

Galera Therapeutics, Inc.

GRTX
Rang in aandelen #33957
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical... Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Aandeelprijs
$17.15
Laatst gesynchroniseerd: 2026-08-03
Marktkapitalisatie
$6.51M
Verandering (1 dag)
9.80%
Verandering (1 jaar)
289.77%
Land
US
Handel Galera Therapeutics, Inc. (GRTX)

Categorie

Winst voor Galera Therapeutics, Inc. (GRTX)
Winst in Mar 2026 TTM: $149.04M
Volgens de meest recente financiële verslagen van Galera Therapeutics, Inc. bedraagt de huidige winst van het bedrijf $149.04M. In 2023 behaalde het bedrijf een winst van $-59.08M, een stijging ten opzichte van de winst van 2022, die $-62.29M bedroeg. De weergegeven winst op deze pagina is de winst vóór rente en belastingen, oftewel EBIT.
Winstgeschiedenis van Galera Therapeutics, Inc. van 2017 tot 2026
Winst aan het einde van elk jaar
Jaar Winst Wijzigen
2026 (TTM) $149.04M -877.84%
2024 $-19.16M -67.57%
2023 $-59.08M -5.15%
2022 $-62.29M -22.65%
2021 $-80.53M 8.49%
2020 $-74.23M 42.93%
2019 $-51.94M 117.33%
2018 $-23.90M -0.03%
2017 $-23.91M 0.00%
Winst van vergelijkbare bedrijven of concurrenten
Bedrijf Winst Winstverschil Land
$5.27B 3,439.37%
US
$1.95B 1,208.85%
NL
- -
CH
- -
KR
$3.01B 1,916.79%
BE